Liver Unit, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.
Gastroenterología - Hepatología, Hospital del Salvador. Universidad de Chile, Santiago, Chile.
Gut. 2022 Jan;71(1):148-155. doi: 10.1136/gutjnl-2020-322161. Epub 2021 Jan 12.
Acute-on-chronic liver failure (ACLF) is characterised by acute decompensation of cirrhosis associated with organ failures. We systematically evaluated the geographical variations of ACLF across the world in terms of prevalence, mortality, aetiology of chronic liver disease (CLD), triggers and organ failures.
We searched EMBASE and PubMed from 3/1/2013 to 7/3/2020 using the ACLF-EASL-CLIF (European Association for the Study of the Liver-Chronic Liver Failure) criteria. Two investigators independently conducted the abstract selection/abstraction of the aetiology of CLD, triggers, organ failures and prevalence/mortality by presence/grade of ACLF. We grouped countries into Europe, East/South Asia and North/South America. We calculated the pooled proportions, evaluated the methodological quality using the Newcastle-Ottawa Scale and statistical heterogeneity, and performed sensitivity analyses.
We identified 2369 studies; 30 cohort studies met our inclusion criteria (43 206 patients with ACLF and 140 835 without ACLF). The global prevalence of ACLF among patients admitted with decompensated cirrhosis was 35% (95% CI 33% to 38%), highest in South Asia at 65%. The global 90-day mortality was 58% (95% CI 51% to 64%), highest in South America at 73%. Alcohol was the most frequently reported aetiology of underlying CLD (45%, 95% CI 41 to 50). Infection was the most frequent trigger (35%) and kidney dysfunction the most common organ failure (49%). Sensitivity analyses showed regional estimates grossly unchanged for high-quality studies. Type of design, country health index, underlying CLD and triggers explained the variation in estimates.
The global prevalence and mortality of ACLF are high. Region-specific variations could be explained by the type of triggers/aetiology of CLD or grade. Health systems will need to tailor early recognition and treatment of ACLF based on region-specific data.
急性肝衰竭(ACLF)的特点是肝硬化急性失代偿合并器官衰竭。我们系统评估了全球范围内 ACLF 的地理分布情况,包括患病率、死亡率、慢性肝病(CLD)病因、诱因和器官衰竭。
我们使用 ACLF-EASL-CLIF(欧洲肝脏研究协会-慢性肝衰竭)标准,于 2013 年 3 月 1 日至 2020 年 7 月 3 日在 EMBASE 和 PubMed 上进行检索。两名调查员独立进行了 CLD 病因、诱因、器官衰竭以及 ACLF 存在/严重程度相关的患病率/死亡率的摘要选择/提取。我们将国家分为欧洲、东亚/南亚和北美/南美。我们计算了汇总比例,使用纽卡斯尔-渥太华量表评估方法学质量和统计学异质性,并进行敏感性分析。
我们共检索到 2369 项研究,其中 30 项队列研究符合纳入标准(43206 例 ACLF 患者和 140835 例无 ACLF 患者)。失代偿性肝硬化患者中 ACLF 的全球患病率为 35%(95%CI,33%至 38%),南亚地区最高(65%)。全球 90 天死亡率为 58%(95%CI,51%至 64%),南美地区最高(73%)。酒精是最常报告的基础 CLD 病因(45%,95%CI,41%至 50%)。感染是最常见的诱因(35%),肾脏功能障碍是最常见的器官衰竭(49%)。敏感性分析显示,高质量研究的区域估计值基本保持不变。设计类型、国家健康指数、基础 CLD 和诱因可以解释估计值的差异。
ACLF 的全球患病率和死亡率均较高。区域特异性差异可能与诱因/CLD 病因类型或严重程度有关。卫生系统将需要根据特定地区的数据,制定出 ACLF 的早期识别和治疗策略。